微信二维码

Boundless Bio Announces $100 Million Oversubscribed Series C Financing co-led by

  • 2023年05月18日
  • Author edit: mf123456

Boundless Bio announced the closing of a $100 million Series C financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and RA Capital Management, with participation from additional new investors, Sectoral Asset Management and Piper Heartland Healthcare Capital. Boundless Bio will use the financing to advance BBI-355, the first ecDNA-directed therapy (ecDTx), through meaningful clinical readouts from its ongoing Phase 1/2 clinical trial in patients with oncogene-amplified cancers.

More ›

Moon Surgical Closes a $31.3 Million Series A Round led by GT Healthcare to Acce

  • 2022年06月08日
  • Author edit: mf123456

Moon Surgical, a pioneer in collaborative robotics, today announced that it has secured $31.3 million in Series A funding. The financing round was led by GT Healthcare Capital & Partners, with participation by Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Cathay Health, and existing investor, Sofinnova Partners.

More ›

【Portfolio News】Immunocore Holdings announces landmark FDA approval of TCR thera

  • 2022年01月27日
  • Author edit: mf123456

GT portfolio company Immunocore Holdings plc (Nasdaq: IMCR) announces approval from the United States Food and Drug Administration (FDA) of KIMMTRAK® (tebentafusp-tebn) for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM), the most common primary cancer within the eye in adults.

More ›

【Portfolio News】Portfolio ONI closes $75 Million Series B Led by ARCH Venture Pa

  • 2022年01月20日
  • Author edit: mf123456

GT portfolio announces the closing of a $75M series B round led by ARCH Venture Partners and Casdin Capital, with participation from Section 32, ARTIS Ventures, Vertical Venture Partners, Axon Ventures and private investors, including Paul Conley. Existing investors, including Oxford Science Enterprises, and GT Healthcare Capital Partners also participated in the round.

More ›

Portfolio unicorns Oxford Nanopore Technologies and Exscientia g

  • 2021年10月11日
  • Author edit: mf123456

We are proud to see two of our portfolio unicorn companies achieving significant milestones of successful initial public offerings. As innovative leaders in respective fields, Oxford Nanopore Technologies and Exscientia has revolutionized and led the technological and translational developments in nanopore sequencing and modernizing drug discovery & developments. We look forward to seeing these innovators taking stride in delivering innovation and improving patient care.

More ›